Could you please provide us with the numbers of patients in relation to the questions mentioned below, for a period of last 12 months:
1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?
2. Of these MS patients, how many have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS;
If you do not code your MS patients in this way, do you have plans to do this?
RRMS
PPMS
SPMS
Not known
3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months? Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Mavenclad (cladribine)
Mayzent (siponimod)
Ocrevus (ocrelizumab)
Plegridy (peginterferon beta-1a)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Vumerity (diroximel fumarate)
Zinbryta (daclizumab)
Ampyra (fampyra)
Ozanimod
4. Of the patients who are receiving Ocrevus (Ocrelizumab) , how many are primary progressive (PPMS)? If unknown, please state unknown.
5. How many patients have been treated with these drugs in the past 6 months, regardless of diagnosis?
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Mavenclad (cladribine)
Mayzent (siponimod)
Ocrevus (ocrelizumab)
Plegridy (peginterferon beta-1a)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Vumerity (diroximel fumarate)
Zinbryta (daclizumab)
Ampyra (fampyra)
Ozanimod
